Analytical Data
-
Gene name
GJD2
- Application
-
Alternative Names
(Connexin-36)(Cx36)(Gap junction alpha-9 protein)
-
Species
Bovine
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q866T7
-
Expression Region
1-321aa
-
Molecular Weight
49.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GJD2, also known as Connexin 47 (Cx47), is a member of the connexin family of proteins, which form gap junctions facilitating intercellular communication. This protein is predominantly expressed in oligodendrocytes within the central nervous system and plays a crucial role in myelination and maintaining the integrity of the blood-brain barrier. The study of GJD2 is significant due to its potential implications in various neurological disorders, including multiple sclerosis and leukodystrophies, where impaired oligodendrocyte function disrupts myelin formation and signaling. Research into GJD2 recombinant protein seeks to better understand its structure-function relationships and the mechanisms underlying its role in cell communication. By producing GJD2 in a recombinant form, scientists can investigate its interactions with other cellular proteins and its impact on cell signaling pathways. Furthermore, GJD2's involvement in disease processes makes it a potential target for therapeutic strategies aimed at restoring normal function in pathological conditions. Understanding the molecular dynamics of GJD2 can also provide insights into the design of drug candidates aimed at enhancing or modulating gap junction communication, ultimately contributing to the development of innovative treatments for demyelinating diseases. Thus, the study of GJD2 recombinant protein represents a critical intersection of molecular biology, pathology, and therapeutic innovation.
